Motley Fool Wealth Management LLC Invests $5.16 Million in Shockwave Medical, Inc. (NASDAQ:SWAV)

Motley Fool Wealth Management LLC bought a new stake in Shockwave Medical, Inc. (NASDAQ:SWAV - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 27,083 shares of the company's stock, valued at approximately $5,164,000. Motley Fool Wealth Management LLC owned 0.07% of Shockwave Medical as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. FMR LLC grew its position in shares of Shockwave Medical by 3.8% in the third quarter. FMR LLC now owns 2,527,893 shares of the company's stock valued at $503,303,000 after purchasing an additional 92,919 shares during the period. Wellington Management Group LLP boosted its position in Shockwave Medical by 33.5% during the third quarter. Wellington Management Group LLP now owns 1,805,771 shares of the company's stock worth $359,529,000 after acquiring an additional 453,048 shares during the last quarter. Artisan Partners Limited Partnership boosted its position in Shockwave Medical by 21.8% during the third quarter. Artisan Partners Limited Partnership now owns 1,398,136 shares of the company's stock worth $278,369,000 after acquiring an additional 250,352 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Shockwave Medical by 35.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 645,634 shares of the company's stock worth $128,546,000 after acquiring an additional 170,369 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in Shockwave Medical by 66.7% during the third quarter. Canada Pension Plan Investment Board now owns 386,321 shares of the company's stock worth $76,917,000 after acquiring an additional 154,637 shares during the last quarter. Institutional investors and hedge funds own 95.35% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on SWAV shares. Needham & Company LLC restated a "hold" rating on shares of Shockwave Medical in a research report on Friday, April 5th. Wolfe Research restated a "peer perform" rating on shares of Shockwave Medical in a research report on Friday, April 5th. Canaccord Genuity Group restated a "hold" rating and set a $335.00 price target (up from $263.00) on shares of Shockwave Medical in a research report on Friday, April 5th. CL King restated a "neutral" rating on shares of Shockwave Medical in a research report on Monday, April 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $335.00 target price (up from $270.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Ten analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $309.11.

Shockwave Medical Stock Up 0.3 %

NASDAQ SWAV traded up $1.01 on Friday, hitting $330.00. 575,689 shares of the stock were exchanged, compared to its average volume of 2,009,896. The company has a quick ratio of 10.73, a current ratio of 11.76 and a debt-to-equity ratio of 1.09. Shockwave Medical, Inc. has a fifty-two week low of $157.00 and a fifty-two week high of $331.58. The company has a market cap of $12.34 billion, a PE ratio of 85.27, a PEG ratio of 2.44 and a beta of 0.92. The company has a 50-day moving average price of $294.88 and a 200-day moving average price of $233.41.

Shockwave Medical (NASDAQ:SWAV - Get Free Report) last issued its earnings results on Thursday, February 15th. The company reported $1.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.24. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The business had revenue of $202.98 million during the quarter, compared to analysts' expectations of $199.43 million. During the same quarter in the prior year, the business posted $3.71 EPS. The company's revenue for the quarter was up 41.0% on a year-over-year basis. Sell-side analysts anticipate that Shockwave Medical, Inc. will post 4.94 EPS for the current fiscal year.

Insider Activity

In other news, CFO Dan Puckett sold 3,406 shares of the company's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $229.76, for a total value of $782,562.56. Following the completion of the transaction, the chief financial officer now owns 27,732 shares in the company, valued at approximately $6,371,704.32. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Douglas Evan Godshall sold 10,000 shares of the company's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $231.56, for a total value of $2,315,600.00. Following the completion of the sale, the chief executive officer now owns 162,762 shares in the company, valued at approximately $37,689,168.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Dan Puckett sold 3,406 shares of the company's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $229.76, for a total transaction of $782,562.56. Following the transaction, the chief financial officer now owns 27,732 shares of the company's stock, valued at approximately $6,371,704.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 89,813 shares of company stock worth $22,863,919. Corporate insiders own 3.40% of the company's stock.

Shockwave Medical Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.